Subscribe to RSS
DOI: 10.1055/s-0039-3401226
A Bayesian risk analysis for Trisomy 21 in isolated choroid plexus cyst: combining a prenatal database with a meta-analysis
Publication History
Publication Date:
27 November 2019 (online)
Introduction:
There is still uncertainty if the isolated choroid plexus cyst (ICPC) contributes to increasing the risk of trisomy 21[1, 2]. The purpose of this study was to quantify the possible additional risk of a fetus with an ICPC for trisomy 21 by combining a large controlled cohort study with data from existent studies.
Methods:
We searched our prenatal database between 2000 – 2014 for all singleton pregnancies between 18+0 and 26+6 gestational weeks with either an isolated choroid plexus cyst (study group) or no abnormality found in the detailed ultrasound scan (control group). We assessed all prenatal karyotyping results and attempted to collect the postnatal outcome reports of all patients. The prevalence of Down syndrome was calculated. By using previous studies that met our inclusion criteria a meta-analysis following the Bayesian Independent Model was created (see figure 1). From this meta-analysis, we computed the posterior predictive distribution of the probability (Trisomy 21 | ICPC)=P1including posterior means, standard deviations, quantiles (2.5%, 50%, and 97.5%). By calculating the posterior of the difference (Δ) between the probability (Trisomy 21 | ICPC) and the probability (Trisomy 21 | Normal Ultrasound) = P2 we investigated the additional risk of an ICPC (ΔB =P1- P2).
Results:
Overall, we detected 1,220 fetuses with an isolated plexus cyst at 19 – 27' weeks of gestational age (GA). In our study group the prevalence of trisomy 21 was 2/1,220 (0.16%, 95% CI: 0.1%-0.6%). The median of the pooled probability of trisomy 21 given isolated PC across the studies included in the meta-analysis was 0.2% (95% CI: 0.1%-0.4%). In the given periods (GA and time) 66,606 (74.8%) out of 89,056 investigated fetuses met the inclusion criteria and had a normal ultrasound result without any abnormality. The Δ between our study group and control group was 0.08% (CIΔA: 0%-0.5%). Including the meta-analysis the median of the posterior distribution of Δ between P1and P2was 0.08% (CIΔB: 0%-0.4%) (ΔB =P1 – P2) (see figure 2).
Discussion:
The posterior distribution of Δ between P1and P2 including the meta-analysis corresponds to showing no difference between the cases and controls (95% CIΔB: 0%-0.4%). The additional risk of a fetus with an ICPC for trisomy 21 is 97.5% likely to be lower than 0.4% (about 1/250). In prenatal counselling the additional risk should be added to the individual risk (based on maternal age, earlier screening test results and sonographic markers) and the diagnostic options including fetal DNA and diagnostic procedures should be discussed according to the posterior individual risk.
![](https://www.thieme-connect.de/media/zgn/2019S01/thumbnails/10-1055-s-0039-3401226-i063.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/zgn/2019S01/thumbnails/10-1055-s-0039-3401226-i064.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Literature:
[1] Coco, C. and P. Jeanty, Karyotyping of fetuses with isolated choroid plexus cysts is not justified in an unselected population. J Ultrasound Med, 2004. 23(7): p. 899 – 906.
[2] Walkinshaw, S., D. Pilling, and A. Spriggs, Isolated choroid plexus cysts–the need for routine offer of karyotyping. Prenat Diagn, 1994. 14(8): p. 663 – 7.